AI-generated · cited to primary sources · not investment advice
Divi's Lab. (532488) Aug 2025 Filing Analysis
Does management do what it says?
The company capitalized ₹114 crores for Phase 1 of the Kakinada project during the current quarter, indicating significant progress toward completing the remaining Phase 1 expenditure. (1 in progress, 1 met across 2 tracked commitments)
“of which assets capitalized for the Phase 1 of Kakinada project amounted to ₹114 crores.”
The facility is currently operational for starting materials and intermediates. Management is preparing to start the qualification of in-house APIs for DMF submissions in the coming quarters. (2 in progress, 1 met across 3 tracked commitments)
“we are qualifying them in Kakinada and then we will start the process, which will take at least 1 to 2 years before we have regulatory approvals in place for Kakinada.”
The product mix for H1 FY26 is currently skewed towards Custom Synthesis (55%) compared to Generics (45%), moving away from the 50/50 balance target as CS growth outpaces generics. (1 in progress across 1 tracked commitment)
“we are thinking it will be about 24 months or maybe 18 months from now. But we are hoping the validations and things would happen sooner.”
The company expects to see commercial volume movement for new generic products like Brivaracetam and Ticagrelor in the next 6 to 12 months. — target: Commercial volume movement
“We think in the next 6 to 12 months, we will start seeing some movement of the product on commercial volumes.”
See the full cited Management analysis of Divi's Lab.
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.